BOZEMAN – A clinical-stage pharmaceutical company in Bozeman announced on July 16 that it was awarded a state grant to test one of its antimicrobial products on skin.
Microbion Corp., focused on the development of products for the treatment of antibiotic-resistant infections and control of microbial biofilms, said it was one of 11 Montana-based companies awarded grants for 2015 from the Montana Board of Research & Commercialization Technology.
The $84,825 award will provide Microbion with the funds needed for 21-day human clinical testing of its lead product, BisEDT Antimicrobial Gel.
“I believe Microbion’s product holds great promise in the prevention and reduction of post-surgical orthopedic infections,” said Daryl Paulson, President and CEO of BioScience Laboratories, a contract research organization that is collaborating with Microbion for the study.
Also based in Bozeman, BioScience Laboratories provides analytical testing and clinical trial services for manufacturers of consumer products, healthcare products and pharmaceuticals.
“BioScience Laboratories has established itself as a leader in the field. It’s a great pleasure to be working with them on this project,” said Brett Baker, President and CEO of Microbion. “This is one more example of the expanding ‘critical mass’ of life-sciences companies located here in Bozeman, and in Montana in general.”
BisEDT Antimicrobial Gel is a member of Microbion’s proprietary bismuth-thiol family of compounds—a new class of antimicrobial agents that in preclinical studies have shown potent activity against a broad spectrum of antibiotic-resistant bacteria, and potent activity against microbial biofilms.